Tag: HER2
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in...
In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour...
Highlights in Development: September 2019
In September 2019, a number of articles discussing antibody-drug conjugates were published in a variety of journals. Here is an overview of some of...
RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial...
Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of the American Society of Clinical...
New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers
Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...
DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...
DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...
MI130004 Shows Positive in vivo Activity against HER2-Expressing Tumors
Positive results of MI130004, a novel antibody-drug conjugate combining trastuzumab via Cys residues through a non-hydrolysable linker, with PM050489, a molecule of marine origin,...
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...
About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...
First Patient Dosed in Pivotal Phase II DESTINY-Gastric01 Study of DS-8201
A first patient has been enrolled in DESTINY-Gastric01 (NCT03329690), a pivotal phase II study in Japan and South Korea evaluating the safety and efficacy...
Alteogen Expects to Initiate Phase I trial of novel HER2 targeting...
In late august, Korean-based Alteogen announced that it expect to initiate a phase I clinical trial for ALT-P7, a novel antibody-drug conjugate or ADC...
Pivotal Phase II Study of DS-8201 in Patients with HER2-Positive Metastatic...
Researchers at Daichi Sankyo initiation the DESTINY-Breast01, a pivotal phase II study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody-drug conjugate...
